4iNLOOK Meimu Meijia Secures Over RMB 100 Million Strategic Investment from Sinopharm Capital

Recently, 4iNLOOK, a colored contact lens brand, announced the completion of a strategic investment of over 100 million yuan from Sinopharm Capital. This round of financing will be used for the company's supply chain investment and brand building, while introducing more top talents to improve technological innovation and new product development, aiming to build a more professional myopia prevention and control product and service system by benchmarking against overseas leading enterprises.

With the increasing pressure of work and study, the number of people with myopia has surged, making myopia prevention and control a national strategy. Due to their lightweight, convenience, aesthetics, and comfort, contact lenses have gained widespread popularity among consumers. Among them, colored contact lenses not only offer basic vision correction and eye care functions but also serve as a fashion statement. They have gradually become a medical device product that combines both technological and fashionable attributes.

At the same time, cosmetic contact lenses have very high industry entry barriers and production process barriers. Since 2012, cosmetic contact lenses have been officially classified as Class III medical devices, in the same category as high-risk interventional medical devices such as artificial heart valves, vascular stents, and orthopedic implants. In addition, the material science, optical design, and production processes of cosmetic contact lenses all possess relatively high technical thresholds. This is a niche medical device industry monopolized by European, American, and Taiwanese companies, and domestic manufacturers in China do not yet have core competitiveness in the production sector.

4inlook, a leader in the colored contact lens industry, has become one of the top brands in this sector due to its advanced product design and integrated online-to-offline business model. Currently, 4inlook operates over 300 specialty chain stores across China, located in mainstream shopping centers in first- and second-tier cities. These stores offer consumers a one-stop shopping experience with more than 200 different design options. Additionally, the company runs online shops on e-commerce platforms like Taobao. With a solid foundation in both online and offline operations, the company has implemented a new retail shopping experience where consumers can place orders online, pick up in-store, make online reservations, and enjoy offline experiences. Furthermore, the company is focusing on supply chain development and innovative optical product research, establishing a world-leading R&D and production base for innovative contact lenses. Upon completing the construction of its flexible supply chain, the company will be able to provide Chinese consumers with fashionable, high-quality domestically produced colored contact lenses at a faster pace.

Regarding the successful completion of this round of financing, Mr. Chen Yu, founder of 4inlook, stated: "For a long time, 4inlook has consistently focused on the needs of contact lens consumers in its business layout and has been committed to integrating technology and beauty in the fields of myopia correction and myopia prevention and control. We aim to provide consumers with the best product options and consumption experience through our optimal product system and business model. We are delighted to have the strategic investment from Sinopharm Capital, which will leverage Sinopharm Group's top brand advantages and industry resources in the healthcare sector. Both parties can closely collaborate in R&D, production, and sales at all stages, propelling the company into a new phase of development. 4inlook will continue to deepen its focus on myopia correction and myopia prevention and control and aims to build a comprehensive domestic leading enterprise in myopia prevention and control by relying on central enterprise resources."

Mr. Li Ke, General Manager of Sinopharm Capital, stated: "The contact lens market is a blue ocean with strong potential for market explosion and vast room for domestic substitution of imported products within the consumer healthcare sector. 4inlook, as a leading enterprise in the colored contact lens industry, possesses abundant brand resources and a marketing system, with advanced layouts in supply chain and new product development. Currently, Sinopharm Group is strategically positioning itself in various life health products and service resources, targeting consumers across China. Investing in 4inlook aligns with Sinopharm Group's long-term development philosophy of creating a product and service system with Sinopharm characteristics, continuously meeting the health and wellness needs of the people. Sinopharm Capital will provide ongoing financial and industrial resource support to empower and assist the company’s rapid growth."